Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD
.
Satellos Bioscience Inc. announced the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders,.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101.
02.01.2024 - WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, .